Company reaches $1.75B valuation as contractors adopt system-level autonomy across complex infrastructure projects

SAN FRANCISCO, Feb. 4, 2026 — Bedrock Robotics, a leader in autonomous construction technology, today announced it has raised $270 million in Series B funding co-led by CapitalG and the Valor Atreides AI Fund, with participation from Xora, 8VC, Eclipse, Emergence Capital, Perry Creek Capital, NVentures (NVIDIA’s venture capital arm), Tishman Speyer, Massachusetts Institute of Technology, Georgian, Incharge Capital, C4 Ventures, and others. This round brings Bedrock’s total funding to over $350 million. The funding will accelerate Bedrock’s mission to transform how general contractors build, from deploying individual autonomous machines to orchestrating fully connected fleets that reshape productivity and safety.

The new funding follows a period of rapid growth for Bedrock. The company emerged from stealth in July 2025 with $80 million in Seed and Series A funding, and in November completed a large-scale supervised autonomy deployment for mass excavation on a 130-acre manufacturing site.

“The construction industry is being asked to build more than it can deliver,” said Boris Sofman, co-founder and CEO of Bedrock Robotics. “Contractors are pulled across competing priorities with the same limited workforce and equipment. This funding helps us scale our development and deployments as we mature autonomy capabilities and the tools for contractors to leverage them. It’s a first step toward a future where entire fleets operate as coordinated systems, fundamentally changing how modern contractors plan, staff, and execute work.”

The industry needs nearly 800,000 workers over the next two years to keep up with demand, with retirements further widening the labor gap. Project backlogs climbed to more than eight months as of December 2025. Against this backdrop, contractors are exploring Bedrock’s autonomy systems across a range of applications spanning port infrastructure, industrial facilities, data centers, and large-scale earthmoving operations across multiple states. On a manufacturing campus in central Texas, Champion Site Prep is currently using the Bedrock Operator to explore how autonomous systems could complement the crews they have today.

“The speed and scale of what’s coming into this region is unlike anything we’ve seen before—automotive, aerospace, AI infrastructure—and these projects don’t wait,” said Trey Taparauskas, President and CEO at Champion Site Prep. “What Bedrock is building will multiply what our crews are capable of. It’s not just about one autonomous machine; it’s the potential to rethink how we coordinate our entire fleet, keep machines running longer, reduce idle time, and improve safety and work zone awareness. That frees up our best people to supervise and strategize so we can take on even more.”

“Hundreds of billions of dollars are flowing into construction, but the workforce simply isn’t there to meet the moment,” said Derek Zanutto, General Partner at CapitalG. “Every major hyperscaler and developer is grappling with how to compress project schedules when labor constraints keep pushing them out. Bedrock’s technology is built on world-class autonomy expertise, and we believe it will unlock the construction velocity this moment requires.”

“What stands out about Bedrock is execution—delivering milestone after milestone with precision and capital efficiency that’s uncommon in this space,” said Antonio Gracias, Founder, CEO, and Chief Investment Officer of Valor Equity Partners. “The companies defining the future of AI, energy, and advanced manufacturing all share a common need: they have to build faster than ever before. We’re confident Bedrock is the team to make that possible.”

In addition to new funding, Bedrock recently expanded its leadership team with key hires. Vincent Gonguet joined as Head of Evaluation, having previously led AI safety and alignment at Meta for all Llama models. John Chu also joined as Head of People after serving in the same role for Waymo’s engineering teams, overseeing headcount growth of 400% while the company expanded globally. The company is targeting its first fully operator-less excavator deployments with customers in 2026—a milestone in autonomous capability for such complex, articulated machines.

About Bedrock Robotics
Founded in 2024, Bedrock Robotics is building the future of autonomous construction. Based in San Francisco, the company is led by former Waymo engineers who helped pioneer the systems that made fully autonomous vehicles a reality on public roads. Now they’re bringing that same deep expertise to construction equipment, developing technology that will enable contractors to improve safety, expand capabilities, and compress schedules to meet growing demand at scale. Bedrock is working alongside leading general contractors to co-develop autonomous solutions to retrofit machines like excavators, bulldozers, and loaders with a vision to make fully autonomous fleets standard on job sites across the country. To learn more, visit www.bedrockrobotics.com.

About CapitalG
CapitalG, Alphabet’s independent growth fund, invests in generational companies transforming the fields of enterprise infrastructure, security, and data; fintech; and consumer services and marketplaces. CapitalG partners with growth stage companies in their transition from startup to scale up through hands-on assistance and connections to Google’s engineering, product, marketing, sales and people operations experts worldwide. More than 3500 Googlers and Alphabet leaders have engaged with CapitalG portfolio companies, including Stripe, CrowdStrike, Databricks, Duolingo, Freshworks, Monzo, UiPath and Zscaler, among others. Learn more at https://capitalg.com.

About Valor Equity Partners
Valor Equity Partners is an operational growth investment firm focused on investing in high-growth companies across various stages of development.  For decades, Valor has served its companies with unique expertise to solve the challenges of growth and scale.  Valor partners with leading companies and entrepreneurs who are committed to the highest standards of excellence and the courage to transform their industries.  For more information on Valor Equity Partners, please visit www.valorep.com.

About Atreides Management
Atreides Management is a crossover investment firm with a long-term perspective, investing in technology and consumer companies across public and private markets. From seed to pre-IPO to publicly listed, Atreides’ model is designed to support mission-driven entrepreneurs throughout a company’s lifecycle. For more information, please visit www.atreidesmgmt.com.

About Champion Site Prep 
Founded in 1985, Champion Site Prep is one of Central Texas’s largest and most experienced commercial earthwork contractors, with more than 3,000 completed projects spanning industrial, multifamily, education, healthcare, retail, and municipal development. As an employee-owned company, Champion is committed to professional-quality excavation and site preparation—coupled with the latest technologies—while maintaining the loyalty and teamwork that have driven nearly four decades of success. To learn more, visit www.idigdirt.com.

Media Contact:
Anjelica Sarkar 
[email protected] 

SOURCE Bedrock Robotics

WHITE PLAINS, N.Y., Feb. 4, 2026 — Manor Park Ventures, a family-backed real estate investment and development firm, today announced the opening of its new headquarters at Switch2 Ten, the newly redeveloped former NYNEX building located at 10 County Center Road in White Plains, New York.

The relocation marks an important milestone for the firm as it continues to expand its development platform and strengthen its presence throughout the Northeast. The new headquarters provides Manor Park Ventures with a modern, flexible environment designed to support collaboration, strategic growth, and long-term operations.

“Our move to Switch2 Ten reflects the evolution of Manor Park Ventures and the direction we are heading,” said Marc Weil, President of Manor Park Ventures. “As our portfolio and partnerships continue to grow, it is important to establish a headquarters that matches the scale, professionalism, and ambition of our firm.”

The firm’s new office features a thoughtfully designed layout with dedicated collaboration areas. Its central White Plains location offers convenient access to Westchester County Airport, regional rail service, key institutional partners, and major transportation corridors.

“This new space allows us to better support our partners, investors, advisors, and development teams while continuing to build a platform designed for durability and long-term growth,” added Weil.

Manor Park Ventures is actively advancing a pipeline of multifamily and mixed-use developments across high-growth markets in the Northeast and Southeast United States, including Knoxville, Tennessee, and Huntsville, Alabama. Supported by family capital and a disciplined, principal-driven investment approach, the firm also evaluates select investments beyond real estate, including technology and specialty operating businesses.

About Manor Park Ventures
Manor Park Ventures is a family-backed real estate investment and development firm focused on the acquisition, development, and operation of strategic real estate assets. Concentrating on opportunistic multifamily development projects throughout the Northeast and Southeast United States, the firm partners with developers and family offices that share a long-term investment philosophy and commitment to value creation.

Contact:
Johanna Greystone
[email protected]
(914) 200-0592

SOURCE Manor Park Ventures

Led by Santé Ventures, the funding will enable beHuman to expand its network of health insurance partners and end customers nationally

MIAMI, Feb. 4, 2026 — beHuman, a physician-led preventive care platform focused on improving early cancer detection for underserved populations, today announced it has raised a $4 million seed round led by Santé Ventures, with participation from DHVP.io. The funding will support beHuman’s expansion beyond its current footprint in the north and southeast, accelerating its mission to make early cancer screening more accessible to patients nationwide.

While early cancer detection has become an increasingly active area of innovation within healthcare, many existing solutions primarily serve affluent, highly engaged consumers. beHuman offers a vertically-integrated solution that is designed to reach a different, and often far larger, population: insured patients who rarely or never receive recommended screenings due to geographic barriers, limited access to care, administrative complexity, or longstanding mistrust of the healthcare system.

“Early detection dramatically improves outcomes, yet millions of insured Americans are still diagnosed too late simply because the system never reaches them,” said Steve Yaskin, Founder and CEO of beHuman. “beHuman was built to meet patients where they are, especially those in rural and underserved communities, by removing friction, restoring trust, and making prevention simple, accessible, and life-saving.”

beHuman integrates virtual clinical care, advanced diagnostic testing, and longitudinal health data access to proactively identify cancer risk and guide patients through appropriate screening pathways. Its agentic AI platform automates key administrative workflows such as eligibility verification, scheduling, chart review, and follow-up, which reduces the burden on clinicians while preserving rigorous, physician-led care.

Importantly, beHuman’s model directly addresses patient concerns around data privacy and misuse, which are especially prevalent in underserved communities. The platform is designed with strict data governance, transparency, and clinical oversight to ensure patient information is used solely to support care.

Early results show that beHuman’s cancer detection rates exceed national averages. By engaging patients earlier in the disease timeline, beHuman is able to uncover risk that would otherwise go undetected until far later stages. Furthermore, the service is covered by most major insurance plans, eliminating cost as a barrier and enabling patients to participate in preventive care without a significant out-of-pocket expense.

Santé Ventures brings deep experience backing healthcare companies that modernize care delivery and improve outcomes at scale. “beHuman is addressing one of healthcare’s most persistent gaps, late cancer detection among populations the system consistently misses,” said Kevin Lalande, Founding Managing Director and Chief Investment Officer at Santé Ventures. “The team’s combination of physician leadership, thoughtful AI automation, and focus on trust and access positions them to deliver meaningful impact nationwide.”

With the new funding, beHuman will:

• Expand into additional states
• Deepen partnerships with leading diagnostic laboratories
• Advance its agentic AI platform to further streamline preventive care workflows
• Scale its physician-led virtual care teams to serve more patients efficiently

As beHuman grows, the company remains focused on its core principle: prevention works best when it is equitable, trusted, and easy to access. To learn more about beHuman, please visit www.behuman.health.

About beHuman
beHuman is a physician-led preventive care platform using AI to make early cancer detection accessible at scale. By combining virtual care, advanced diagnostics, and automated workflows, beHuman helps underserved and under-screened patients identify cancer risk earlier and navigate screening with confidence. The platform is covered by most insurance plans and currently operates across multiple U.S. states.

About Santé Ventures
Founded in 2006, Santé Ventures is a specialized healthcare and life sciences investment firm with over $1 billion in capital under management. The firm invests in early-stage companies developing innovative new medical technologies, biotechnologies, and digitally enabled healthcare services. Recent Santé successes include Laminar (Johnson & Johnson), Farapulse (Boston Scientific), Healthcare Highways – CerpassRx (Nomi Health), Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), Molecular Templates (MTEM), AbVitro (Bristol Myers Squibb), and Explorys (IBM Corp). Santé invests nationally and has offices in Austin, TX and Boston, MA. For more information, please visit www.sante.com.

Media Contact
Ryan Walker
R.J. Walker & Co.
[email protected]

SOURCE beHuman

$52M equity adds to previously announced $165M Series A

New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures, and Alderline Group

SPRING HOUSE, Pa., Feb. 4, 2026 — Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the closing of a $52 million Series A extension.

New investor Andreessen Horowitz (a16z) joined Third Arc Bio’s existing world-class investor syndicate to further validate the company’s approach to deliver transformational therapies for patients. As part of the financing, a16z General Partner, Jorge Conde, joins Third Arc Bio’s Board of Directors. Proceeds from the financing will enable Third Arc Bio to accelerate its I&I portfolio and deliver additional oncology programs into the clinic.

“Third Arc represents a shift toward more precise immune modulation—moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease,” said Jorge Conde, General Partner at a16z. “The company’s platforms, combined with a team that has repeatedly translated complex immunology into approved medicines, reflect a rigorous, patient-driven approach to building biologics that can improve both efficacy and safety across oncology and immune-mediated disease.”

Since its launch in 2022 with seed financing from Omega Funds, Third Arc Bio has assembled a highly experienced team with a proven track record of drug discovery and development, alongside an innovative platform and a pipeline of multispecific antibodies. The company’s lead asset, ARC101, is a bispecific T cell engager targeting CLDN6 currently in Phase 1 dose escalation in patients with advanced solid tumors.

“This financing allows us to maintain momentum across our expanding oncology portfolio while rapidly advancing our next-generation I&I assets into first-in-human studies,” said Peter F. Lebowitz, MD, PhD, Chief Executive Officer of Third Arc Bio. “By parallel-tracking programs, we can more efficiently validate the full potential of our platforms, rapidly generate proof-of-concept data, and deliver innovative therapies for patients with significant unmet need.”

Third Arc Bio’s approach to I&I is anchored by its ARCTag (Tethered Agonist) Platform, which leverages multispecific antibodies to localize immune modulation directly to sites of disease. This targeted activity represents a meaningful advance beyond conventional systemic autoimmune therapies, offering the potential for enhanced efficacy and therapeutic index.

About Third Arc Bio
Third Arc Bio is a clinical stage biotech company developing multifunctional antibodies that generate immune synapses to precisely activate or inhibit T cells. The lead program ARC101, is a bispecific T cell engager currently being evaluated in a Phase 1 trial for cancer patients with solid tumors expressing CLDN6. The company’s drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging novel technologies that power a pipeline of high value therapeutics. The Third Arc Bio platforms include a solid tumor ARCStim Platform and an immunology & inflammation (I&I) ARCTag Platform that offers precision immune regulation to achieve superior efficacy and safety. To learn more, visit www.thirdarcbio.com.

Media Contact
Peg Rusconi, Deerfield Group
[email protected] 

SOURCE Third Arc Bio

Fuels the company’s Collaborative Intelligence^™ platform growth

FORT LAUDERDALE, Fla., Feb. 4, 2026 — SynthBee, Inc., a stealth start-up pioneering its Collaborative Intelligence^™ (CI^™) platform, today announced the completion of $100 million in funding with Crosspoint Capital Partners, LP (Crosspoint Capital), following its initial $20 million seed funding and an additional $80 million secured last week. Crosspoint Capital is an investment firm focused on the cybersecurity, privacy, infrastructure and AI software markets. 

This investment accelerates SynthBee’s mission of building its proprietary CI^™ technology platform, expansion into new markets, and continued investment in talent. SynthBee’s current and future customers span medical technology and healthcare, aerospace and defense, advanced manufacturing, automotive, financial services, and other key technology and media industries.

“At Crosspoint, we were blown away by the power of the business case for the customer. The value proposition and time-to-value cannot be ignored,” said Andre Fuetsch, Managing Director, Crosspoint Capital. “We’re incredibly excited about what the SynthBee team has created, its cohort of industry-leading customers, and the scale of the opportunity ahead. The team has invented a new way for organizations to harness intelligence at speed and with confidence. SynthBee’s differentiated CI^™ platform is precisely the kind of bold, grounded innovation Crosspoint [Capital] wants to back for the long term.” 

SynthBee’s mission is to help enterprises across key markets radically accelerate innovation across the product and technology lifecycles, from concept to manufacturing. The Company was founded by Rony Abovitz, the entrepreneur behind MAKO Surgical (acquired by Stryker for $1.65 billion) and Magic Leap, both recognized for redefining their categories in surgical robotics and spatial computing/XR. SynthBee’s CI^™ platform aims to bring that same level of innovation and impact to a broad range of businesses in the United States and around the free world.

“SynthBee’s customers operate in mission-critical, high-performance areas across complex, regulated markets,” said Rony Abovitz, President and CEO at SynthBee. “Our proprietary CI^™ platform empowers businesses to solve complex scientific, engineering, design, compliance and creative challenges at extreme speed, with high accuracy, high privacy, high reliability, under human control and with clear auditability. This investment enables us to deepen our work with businesses across numerous vertical markets that require secure, high-reliability systems for their most important engineering, manufacturing, and field operations.”

About Crosspoint Capital
Crosspoint Capital is an investment firm focused on the cybersecurity, privacy, infrastructure and AI software markets. Crosspoint has assembled a group of successful operators, investors and sector experts to partner with foundational technology companies and drive differentiated returns. Crosspoint has offices in Menlo Park, CA and Boston, MA. For more information visit: www.crosspointcapital.com

About SynthBee, Inc.
SynthBee, Inc. is building safe, scalable, and reliable computing intelligence to amplify and accelerate human innovation. www.synthbee.com

Contact
[email protected]

SOURCE SynthBee, Inc.

MAGNOLIA, Texas, Feb. 4, 2026 — Stratus^® Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced a $10 million Series B financing. The financing was led by Wasatch Health Partners, a healthcare-focused investment firm pursuing growth equity and lower middle-market buyout strategies. Wasatch Health Partners invested through its Growth Fund and previously provided a $25 million convertible debt facility through its Structured Capital platform.

The proceeds from the Series B financing will be used to complete development of the Stratus Medical RF Generator and neurovasis^™ basivertebral nerve ablation (BVNA) technology, expand and protect the company’s valuable patent portfolio, and fund a clinical study. These high-potential technologies will allow Stratus Medical to better serve its rapidly growing customer base while leveraging the proven and patented NIMBUS^® RF Multitined Expandable Electrode (Nimbus) design.

Vertebrogenic low back pain develops when the vertebral endplates in the spine become damaged, often as a result of progressive degeneration over time. Current treatment options include medications, physical therapy, and basivertebral nerve ablation (BVNA). It is estimated that more than five million people in the United States suffer from vertebrogenic back pain.

The Stratus Medical RF Generator and neurovasis BVNA technologies are under development and have not been submitted, evaluated, or cleared by the FDA.

Luke Larsen, Vice President at Wasatch Health Partners, said, “We are pleased to expand our partnership with Stratus Medical. The company has demonstrated strong execution, consistent revenue growth, and meaningful progress across technology development and clinical initiatives. We believe the management team is well positioned to continue building on this momentum.”

Bret Boudousquie, CEO of Stratus Medical, commented, “We appreciate the long-term relationship with Wasatch Health Partners and their continued belief in our mission to help chronic pain patients by advancing RF technology. Stratus Medical is proud to work with outstanding physicians, hospitals, and ASCs, and we are anxious to deliver additional value with our future RF technologies that this financing enables us to complete.”

Doug Beall, MD, Director of Interventional Radiology, Clinical Radiology of Oklahoma, commented, “I started using Nimbus in 2020 for radiofrequency ablation pain treatments due to its larger ablation zone and ease of use. In 2022, I started providing scientific input on the neurovasis project. In 2024, my colleagues and I published the first scientific article describing the neurovasis BVNA technique utilizing CT reconstruction to assess device placement. This technology builds on the Nimbus multitined design and has the potential to offer faster, easier-to-use RF treatments and cost reductions for hospitals and ASCs.”

About Stratus Medical
Stratus Medical is a medical device company focused on reducing pain and improving the quality of life for chronic pain patients through innovation. The Company has been recognized for revenue growth and innovation by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, and The Houston Business Journal. Nimbus has rapidly gained market share in the US and other countries based on ease of use, reduced procedure times, and its large-volume lesion designed to provide sustained pain relief. Stratus Medical is headquartered in Magnolia, Texas.

About Wasatch Health Partners
Wasatch Health Partners is a healthcare-focused investment firm investing in medical device, life science, and outsourced medtech, and pharmaceutical services companies through growth equity, lower middle-market buyouts, and structured capital strategies. The firm is headquartered in Salt Lake City, Utah.

Media Contact
Cody Jorgensen
Marketing Communications
Stratus Medical
346-703-0642
[email protected]
https://stratusmedical.com 

SOURCE Stratus Medical

MIDDLETON, Wis., Feb. 3, 2026 — Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences’ reach within the US market, particularly in the MD office setting, and accelerate the development of its proprietary SAM^™ Antimicrobial Technology platform to minimize wound care complications.

To learn more about Imbed Biosciences and its innovative wound care technologies, please visit www.imbedbio.com.

“The strategic investment from BioLab Holdings marks a pivotal moment for Imbed Biosciences,” said Terry Bromley, Imbed Biosciences CEO, “significantly expanding our reach of within the critical U.S. market, especially in the MD Office setting, and empowering us to further advance our technology platform, unique in its ability to integrate multiple therapeutic agents into a one-product solution to address unmet needs in wound care.”

Advancing Wound Care Solutions

This strategic investment enables Imbed Biosciences to further expand its product platform, designed to help achieve zero wound‑care complications, supported by a growing body of compelling clinical evidence. Imbed Biosciences holds a unique position in the skin substitute market, offering the only fully synthetic and antimicrobial solution of its kind. The investment from BioLab is centered around Imbed’s Microlyte^® product, which is focused on chronic wound indications and engineered for effective bioburden reduction as well as cell proliferation during the crucial “scaffolding” phase of healing.

“At BioLab, we invest in platforms that have the potential to elevate how clinicians approach wound care,” said Jaime Leija, president and CEO of BioLab Holdings. “Imbed’s SAM^™ technology represents a combination of scientific rigor, practical design, and long‑term scalability. We see tremendous opportunity to support its adoption in physician office settings, while helping accelerate solutions that simplify care delivery and improve outcomes for patients.”

The investment underscores a shared commitment to advancing patient outcomes in wound care through innovative, effective solutions. For details on BioLab Holdings Inc.’s announcement, refer to their press release.

Media Contact: Hillary Rush, VP Marketing, Email: [email protected]

About Imbed Biosciences
Imbed Biosciences is a privately held medical device company advancing the next generation of wound care through its SAM^™ Antimicrobial Technology. The company’s platform incorporates multiple therapeutic agents into ultra‑thin, biocompatible matrices that support skin regeneration in both chronic and acute wounds. Imbed’s expanding product portfolio is engineered to reduce infection risk, alleviate pain, and promote healing across the entire wound‑care continuum.

About BioLab Holdings, Inc.
BioLab Holdings, Inc. is a Phoenix-based medical manufacturer specializing in wound protection. Its products—including Membrane Wrap – Lite ^™ and Membrane Wrap ^™ use human tissue allograft derived from amniotic membrane to provide structural tissue for wound protection. BioLab’s mission is optimize the standard of care through innovations grounded in science, compassion, and collaboration.

SOURCE Imbed Biosciences

Based on the tactics of U.S. intelligence agencies, GenLogs applies AI to a nationwide sensor network, satellites, and other data streams to drive greater efficiency and defend against crimes

ARLINGTON, Va., Feb. 3, 2026 — GenLogs, whose innovative Truck Intelligence™ technology is being deployed across industries to make supply chains safer and stronger, announced it has closed $60 million in Series B funding. The round was led by Battery Ventures with participation by IVP, Cathay Innovation, and 9Yards, as well as existing investors Venrock, Steel Atlas, HOF Capital, TitletownTech, and Autotech Ventures. GenLogs previously raised $21 million in Seed and Series A funding.

The company will use the new funds to continue building out its core platform—powered by its privacy-enabled network of roadside sensors—and extend capabilities to shippers, insurers, governments, and financial institutions. Current customers include Fortune 500 companies across these sectors, including logistics and supply-chain expert J.B. Hunt, trucking company Werner Enterprises, insurer AIPSO, and Jacksonville Port Authority (JAXPORT).

“The trillion-dollar trucking industry links every sector of our economy, but it is highly fragmented in its composition and still analog in its operations,” said Ryan Joyce, a veteran former CIA officer who co-founded GenLogs in 2023 and serves as CEO. “GenLogs is applying many aspects of the U.S. intelligence community’s playbook to drive total visibility in the trucking industry, resulting in more efficiency, better pricing, and protection against fraud and $35 billion in annual cargo theft.”

To do this, GenLogs leverages trillions of data points collected from millions of satellites and sensors—including cameras that sit on roadside infrastructure and ports nationwide that capture real-time data on trucks. The company then applies proprietary AI to expose patterns that enable customers to conduct better carrier sourcing, vetting, and underwriting. By understanding the true movements of a fleet, customers can verify that these patterns match the carrier’s digital footprint. This intelligence ensures that customers know the carriers they are using are real and operating on the roads with the right equipment.

GenLogs uses a three-step privacy filter to ensure that its cameras collect data only on commercial vehicles. The technology deletes any footage of private vehicles before screening for commercial markings, such as a USDOT number, and blurs the vehicle’s windows to prevent biometric person identification.

Beyond diverse commercial applications, GenLogs has worked extensively with both federal and state law enforcement over the last year to combat human trafficking, cargo theft, and narcotics smuggling. In one case, state law enforcement used GenLogs to track a truck engaged in interstate sex trafficking and ultimately recovered a female minor from the truck. In another case, a counter-narcotics agency was able to use GenLogs’ platform to uncover a drug smuggling network and ultimately raid multiple safehouses, resulting in a dozen arrests.

“In a remarkably short time, GenLogs has developed a novel data set of great commercial and prosocial value,” said Marcus Ryu, general partner at Battery Ventures, who will be joining GenLog’s board of directors. “Informed by their intelligence training, Ryan and his co-founders had the insight to recognize that the mission-critical work of multiple industries could be transformed by an incorruptible ground truth of nationwide trucking operations and freight movement.”

For more information, visit www.genlogs.io.

About GenLogs

GenLogs is the Truck Intelligence™ platform leveraging AI on a nationwide network of roadside sensors, satellites, and proprietary datasets. GenLogs tracks all commercial vehicle patterns in the United States in order to drive better business outcomes for customers in trucking, logistics, insurance, commercial real estate, financial institutions, and governments.

SOURCE GenLogs

OAK RIDGE, Tenn., Feb. 3, 2026 — LIS Technologies Inc.‘s (LIST) recently announced laser-based uranium enrichment facility represents a $1.38 billion investment in Oak Ridge, Tennessee, and is expected to create more than 200 jobs in the area. Through its role as Lead Project Integrator, Enveniam will coordinate and lead project management, planning, licensing, design, construction, site readiness, operations readiness and delivery for the facility — the first of its kind in the U.S. and one of the largest nuclear-related investments in Tennessee history.

Alongside Tennessee Gov. Bill Lee, LIST announced its intent to develop the facility on a 206-acre site formerly known as Duct Island and now renamed “LIST Island,” located at the historic K-25 uranium enrichment plant. Enveniam, a BCP portfolio company, brings decades of experience in nuclear engineering and operations and will support LIST as it advances its patented laser isotope separation technology to meet growing demand for domestic enrichment and support U.S. energy and defense needs.

“We are proud to play a key role in this historic investment and to help bring this transformative technology to life,” said Doug Freund, President and CEO of Boston Government Services and Executive Officer of Enveniam. “This project represents a major step forward for U.S. energy independence and nuclear innovation, and we’re honored to support LIST in shaping a more secure and resilient domestic fuel cycle.”

As a trusted Lead Project Integrator for high-stakes, multidisciplinary programs, Enveniam integrates facilities, technology, suppliers and operations from concept through commissioning. Its promise is delivery certainty — cohesive, mission-ready systems that meet requirements and deliver on cost and schedule commitments.

Subject to licensing, permitting and final investment decisions, LIST intends to begin site preparation and construction in 2026, with initial commercial operations targeted before 2030. This announcement follows the company’s selection in the U.S. Department of Energy’s Low-Enriched Uranium (LEU) Enrichment Acquisition Program and further positions Oak Ridge at the forefront of nuclear energy advancement.

For more information on LIS Technologies and this announcement, visit laseristech.com. To learn more about Enveniam and its role in advancing critical energy and infrastructure initiatives, visit enveniamsolutions.com.

About Enveniam

Enveniam advances the nation’s focus on energy dominance and national security through engineering, technology and deep domain expertise. As a Lead Project Integrator, the company delivers integrated solutions across federal and energy markets, including nuclear, oil, natural gas, renewables and critical infrastructure. A BCP portfolio company, Enveniam brings the scale, agility and depth needed to address the world’s most pressing energy and security challenges. For more information, visit enveniamsolutions.com.

Media Contact
Annie Landry
(225) 931-0215
[email protected]

SOURCE Enveniam